John Libbey Eurotext

Annales de Biologie Clinique

Intérêt clinique du CA 15-3 pour la détection des métastases des cancers du sein nouvellement diagnostiqués Volume 75, numéro 4, Juillet-Août 2017

  • [1] Institut national du Cancer. Les cancers en France. Boulogne-Billancourt: Institut national du Cancer; 2016. Édition 2015
  • [2] Institut national du Cancer. Cancer du sein infiltrant non métastatique : questions d’actualité, rapport intégral. Boulogne-Billancourt: Institut national du Cancer; 2012.
  • [3] Carlson R.W., Allred D.C., Anderson B.O., Burstein H.J., Carter W.B., Edge S.B. National comprehensive cancer network. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9:136-222.
  • [4] HAS (Haute Autorité de santé). Guide ALD 30. Cancer du sein. HAS; 2010.
  • [5] Mauriac L., Luporsi E., Blanc-Vincent M.P., Cutuli B., Fourquet A., Garbay J.R. Standards, options et recommandations (SOR). Cancers du sein infiltrants non métastatiques. Paris: Ed. John Libbey, Eurotext; 2001. 2 éditione
  • [6] Bast R.C., Ravdin P., Hayes D.F., Bates S., Fritsche H. Jr., Jessup J.M. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the american society of clinical oncology. J Clin Oncol. 2001;19:1865-1878.
  • [7] Le Guellec S., Perallon R., Alunni J.P., Charitansky H., Leaha C., Gonzalez A.M. Neoadjuvant treatment of breast cancer: implications for the pathologist. Ann Pathol. 2011;31:442-454.
  • [8] Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J. American society of clinical oncology/College of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
  • [9] Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC cancer staging manual. New York: Springer; 2010. 7th ed
  • [10] Delacour H., Servonnet A., Perrot A., Vigezzi J.F., Ramirez J.M. ROC (receiver operating characteristics) curve: principles and application in biology. Ann Biol Clin. 2005;63:145-154.
  • [11] Basuyau J.P., Blanc-Vincent M.P., Bidart J.M., Daver A., Deneux L., Eche N. Standards, options et recommandations (SOR) : marqueurs tumoraux sériques du cancer du sein. Bull Cancer. 2000;87:723-737.
  • [12] Safi F., Kohler I., Rottinger E., Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer. 1991;68:574-582.
  • [13] Dnistrian A.M., Schwartz M.K., Greenberg E.J., Smith C.A., Schwartz D.C. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Tumour Biol. 1991;12:1282-1290.
  • [14] Wojtacki J., Dziewulska Bokiniec A., Skokowski J., Ciesielski D. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study. Neoplasma. 1994;41:213-216.
  • [15] Devine P.L., Duroux M.A., Quin R.J., McGuckin M.A., Joy G.J., Ward B.G. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Breast Cancer Res Treat. 1995;34:245-251.
  • [16] Pavesi F., Lotzniker M., Scarabelli M., Mauro E., Visconti G., Nicolato E. Circulating CA 549 and other associated antigens in breast cancer patients. Oncology. 1994;51:18-21.
  • [17] Eskelinen M., Kataja V., Hämäläinen E., Kosma V.M., Penttilä I., Alhava E. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Anticancer Res. 1997;17:1231-1234.
  • [18] Garcia M.B., Blankenstein M.A., van der Wall E., Nortier J.W., Schornagel J.H., Thijssen J.H. Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer. Breast Cancer Res Treat. 1990;17:69-76.
  • [19] Giovanella L., Ceriani L., Giardina G., Bardelli D., Tanzi F., Garancini S. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med. 2002;40:298-303.
  • [20] D’Alessandro R., Roselli M., Ferroni P., Mariotti S., Spila A., Aloe S. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat. 2001;68:9-19.
  • [21] Giai M., Roagna R., Ponzone R., Biglia N., Sgro L., Perona M. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res. 1996;16:875-881.
  • [22] O’Hanlon D.M., Kerin M.J., Kent P.J., Skehill R., Maher D., Grimes H. A prospective evaluation of CA15-3 in stage I carcinoma of the breast. J Am Coll Surg. 1995;180:210-212.
  • [23] Colomer R., Ruibal A., Genollà J., Salvador L. Circulating CA 15-3 antigen levels in non-mammary malignancies. Br J Cancer. 1989;59:283-286.
  • [24] Boccara C., Basuyau J.P., Brunelle P., Bastit P., Berry M., Chevrier A. Apport du CA 15-3 en cancérologie mammaire. Immun Biol Spec. 1998;13:19-25.
  • [25] Konan S., Goussot V., Desmoulins I., Lorgis V., Coutant C., Fumoleau P. Clinical value of CA 15-3 for early detection of relapse in locally advanced breast cancer. Bull Cancer. 2015;102:834-844.
  • [26] Molina R., Barak V., van Dalen A., Duffy M.J., Einarsson R., Gion M. Tumor markers in breast cancer. European group on tumor markers recommendations. Tumour Biol. 2005;26:281-293.
  • [27] Gion M., Mione R., Dittadi R., Fasan S., Pallini A., Bruscagnin G. Evaluation of CA15/3 serum levels in breast cancer patients. J Nucl Med Allied Sci. 1986;30:29-36.
  • [28] Touitou Y., Darbois Y., Bogdan A., Auzéby A., Keusseoglou S. Tumour marker antigens during menses and pregnancy. Br J Cancer. 1989;60:419-420.
  • [29] Brennan M.E., Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast. 2012;21:112-123.
  • [30] Cochet A., Dygai-Cochet I., Riedinger J.M., Humbert O., Berriolo-Riedinger A., Toubeau M. F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41:428-437.
  • [31] Riegger C., Herrmann J., Nagarajah J., Hecktor J., Kuemmel S., Otterbach F. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2012;39:852-863.
  • [32] Talbot J.N., Grahek D. Update of “Standards, options and recommendations” for FDG-PET in breast and gynaecological cancers. Gynecol Obstet Fertil. 2006;34:434-436.
  • [33] Riedl C.C., Slobod E., Jochelson M., Morrow M., Goldman D.A., Gonen M.4. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55:1578-1583.
  • [34] Alberini J.L., Lerebours F., Wartski M., Fourme E., Le Stanc E., Gontier E. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009;115:5038-5047.
  • [35] Lee J.S., Park S., Park J.M., Cho J.H., Kim S.I., Park B.W. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers. Breast Cancer Res Treat. 2013;141:477-484.
  • [36] Tampellini M., Berruti A., Gorzegno G., Bitossi R., Bottini A., Durando A. Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumour Biol. 2001;22:367-373.
  • [37] Geng B., Liang M.M., Ye X.B., Zhao W.Y. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol. 2015;3:232-236.
  • [38] Bensouda Y., André F., Boulet T., Al-Ghuzlan A., Conforti R., Troalen F. Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status. Bull Cancer. 2009;96:923-928.
  • [39] Tampellini M., Berruti A., Gerbino A., Buniva T., Torta M., Gorzegno G. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer. 1997;75:698-702.
  • [40] Shao Y., Sun Y., He Y., Liu C., Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 2015;10:e0133830.
  • [41] Wu S.G., He Z.Y., Zhou J., Sun J.Y., Li F.Y., Lin Q. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23:88-93.
  • [42] Velaiutham S., Taib N.A., Ng K.L., Yoong B.K., Yip C.H. Does the pre-operative value of serum A15-3 correlate with survival in breast cancer? Asian Pac J Cancer Prev. 2008;9:445-448.
  • [43] Duffy M.J., Duggan C., Keane R., Hill A.D., McDermott E., Crown J. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50:559-563.
  • [44] Duffy M.J., Shering S., Sherry F., McDermott E., O’Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers. 2000;15:330-333.
  • [45] Shering S.G., Sherry F., McDermott E.W., O’Higgins N.J., Duffy M.J. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer. 1998;83:2521-2527.
  • [46] Di Gioia D., Dresse M., Mayr D., Nagel D., Heinemann V., Stieber P. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. 2015;440:16-22.
  • [47] Martín A., Corte M.D., Alvarez A.M., Rodriguez J.C., Andicoechea A., Bongera M. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res. 2006;26:3965-3971.
  • [48] Park B.W., Oh J.W., Kim J.H., Park S.H., Kim K.S., Kim J.H. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19:675-681.
  • [49] Petrelli F., Barni S. Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol. 2012;29:3282-3290.
  • [50] Badwe R., Hawaldar R., Nair N., Kaushik R., Parmar V., Siddique S. Locoregional treatment no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380-1388. versus
  • [51] King T.A., Lyman J., Gonen M., Reyes S., Shelley Hwang E.S. A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol. 2016;34:abst 1006. (Suppl.)
  • [52] Gonçalves A., Moretta J., Eisinger F., Bertucci F. Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting. Bull Cancer. 2013;100:1295-1310.